Type I interferons (IFNs) are pleiotropic cytokines with potent antiviral properties that also promote protective T cell and humoral immunity. Paradoxically, type I IFNs, including the widely expressed IFNβ, also have immunosuppressive properties, including promoting persistent viral infections and treating T-cell-driven, remitting-relapsing multiple sclerosis. Although associative evidence suggests that IFNβ mediates these immunosuppressive effects by impacting regulatory T (Treg) cells, mechanistic links remain elusive. Here, we found that IFNβ enhanced graft survival in a Treg-cell-dependent murine transplant model. Genetic conditional deletion models revealed that the extended allograft survival was Treg cell-mediated and required IFNβ signaling on T cells. Using an in silico computational model and analysis of human immune cells, we found that IFNβ directly promoted Treg cell induction via STAT1- and P300-dependent Foxp3 acetylation. These findings identify a mechanistic connection between the immunosuppressive effects of IFNβ and Treg cells, with therapeutic implications for transplantation, autoimmunity, and malignancy.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8917088PMC
http://dx.doi.org/10.1016/j.immuni.2022.01.011DOI Listing

Publication Analysis

Top Keywords

allograft survival
8
cell induction
8
foxp3 acetylation
8
immunosuppressive effects
8
treg cells
8
ifnβ
6
interferon-β acts
4
acts directly
4
directly t cells
4
t cells prolong
4

Similar Publications

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is one of the main treatment methods for hematological malignancies. With the continuous improvement and popularization of transplantation technology, it has brought hope for prolonging the lives and improving the survival rate of patients with hematological malignancies. However, postoperative invasive fungal infection (IFI) is the most common infectious complication and the main cause of death, with difficult early diagnosis and extremely high mortality.

View Article and Find Full Text PDF

Objective: To analyze the risk factors of primary poor graft function (PGF) after allogeneic hematopoietic stem cell transplantation (allo-HSCT) in patients with myeloid malignancies and the impact of primary PGF on survival.

Methods: The clinical data of 146 patients with myeloid malignancies who underwent allo-HSCT in our hospital from January 2015 to December 2021 were retrospectively studied. Some relevant clinical parameters which may affect the development of primary PGF after allo-HSCT were selected for univariate and multivariate analysis, as well as performed survival analysis.

View Article and Find Full Text PDF

Targeting T helper 17 cells: emerging strategies for overcoming transplant rejection.

Clin Transplant Res

December 2024

Department of Pathology, College of Medicine, The Catholic University of Korea, Seoul, Korea.

Solid organ transplantation has significantly improved the survival rate of patients with terminal organ failure. However, its success is often compromised by allograft rejection, a process in which T helper 17 (Th17) cells play a crucial role. These cells facilitate rejection by enhancing neutrophil infiltration into the graft and by activating endothelial cells and fibroblasts.

View Article and Find Full Text PDF

Current desensitization and maintenance immunosuppression regimens for kidney transplantation in sensitized individuals show limited ability to control the posttransplant humoral response, resulting in high rates of antibody-mediated rejection (ABMR) and graft failure. Here, we showed that anti-CD154 monoclonal antibody (mAb)-based immunosuppression more effectively controlled allograft rejection and humoral rebound in a highly sensitized nonhuman primate kidney transplantation model compared with tacrolimus-based standard-of-care (SOC) immunosuppression. Desensitization with an anti-CD154 mAb (5C8) and a proteasome inhibitor led to decreased donor-specific antibodies (DSAs) and disruption of lymph node germinal centers with reduction of proliferating, memory, and class-switched B cells as well as T follicular helper cells.

View Article and Find Full Text PDF

Outcomes of Scapular Osteosarcoma.

Anticancer Res

January 2025

Department of Orthopedic Surgery, Mayo Clinic, Rochester, MN, U.S.A.;

Background/aim: Scapular osteosarcoma is a rare malignancy, and the understanding of its optimal treatment strategies and long-term outcomes remains limited. The purpose of the current study was to evaluate our institutional experience.

Patients And Methods: We reviewed 14 patients (8 females, 5 males; mean age 44±17 years) treated for scapular osteosarcoma from 1985 to 2022.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!